Evidence map›Paper›PMID 40006526›Full record

ArticlePharmaceutics2025

Improving the Working Models for Drug-Drug Interactions: Impact on Preclinical and Clinical Drug Development.

James Nguyen, David Joseph, Xin Chen, Beshoy Armanios, Ashish Sharma, Peter Stopfer, Fenglei Huang

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James NguyenBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
David JosephBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Xin ChenBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Beshoy ArmaniosBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.ORCID 0009-0009-6062-7546
Ashish SharmaBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Peter StopferBoehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riß, Germany.ORCID 0000-0003-0144-0895
Fenglei HuangBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.ORCID 0000-0002-0642-9401

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug–drug interactionexcretionIVIVE

Identifiers

PMID40006526
PMCPMC11859687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.